Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002524 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00002524: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00002524 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002524, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Cisplatin
- BIOLOGICAL Bleomycin Sulfate
- DRUG Cytarabine
- BIOLOGICAL Filgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 1993-06 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002524
The ClinicalTrials.gov registry entry for NCT00002524 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00002524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002524 about?
NCT00002524 is a clinical study titled "Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lym...
What is the current status of trial NCT00002524?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 1993-06. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00002524?
The interventions under investigation include: Cyclophosphamide (DRUG), Cisplatin (DRUG), Bleomycin Sulfate (BIOLOGICAL), Cytarabine (DRUG), Filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002524?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.